Essentials
• The pathophysiology of type 2M von Willebrand disease (VWD) is poorly understood.
• Sequence variations in type 2M VWD subjects were characterized.
• A high degree of clinical and laboratory variability exists within type 2M VWD variants.
• Some type 2M variants may share features of type 2A VWD.
Summary. Background: von Willebrand factor (VWF) is a multimeric coagulation factor that tethers platelets to injured subendothelium. Type 2M von Willebrand disease (VWD) is characterized by a qualitative defect in VWF with preserved multimer distribution. Objectives: Through the Zimmerman Program for the Molecular and Clinical Biology for VWD, five VWF sequence variations were studied in subjects diagnosed with type 2M VWD. Methods: Bleeding phenotype was assessed using the ISTH bleeding assessment tool. Full-length VWF gene sequencing was performed for each subject. Each variant was placed into a recombinant VWF vector using site-directed mutagenesis and expressed in HEK293T cells as homozygous or heterozygous VWF. Variant expression, collagen binding and platelet GPIba binding were studied through ELISA assays. Multimer analysis was performed by gel electrophoresis. Results: Bleeding scores were elevated for all subjects except for the p.P1162L and p.R1374C
variants. Although all had reduced VWF ristocetin cofactor activity/VWF antigen ratios on plasma testing, recombinant VWF did not show a classic type 2M phenotype for any of the five variants. Homozygous expression of variants p.D1283Y, p.R1349C, p.R1374C and p.I1453N was consistent with type 2A VWD, although all had normal expression as heterozygous recombinant VWF. Variant p.P1162L had normal VWF expression and function, consistent with the lack of bleeding symptoms. Conclusions: Although originally classified as type 2M VWD, these homozygous recombinant VWF variants do not fulfill complete 2M VWD diagnostic criteria. A better classiIntroduction von Willebrand factor (VWF) is a multimeric coagulation factor comprised of high-molecular-weight multimers (HMWM) that connect platelets to damaged subendothelium through collagen and platelet ligand sites. VWF binds to platelet glycoprotein Ib (GPIb) via the A1 domain [1] . VWF binds to collagens 1 and 3 via the A3 domain, and collagens 4 and 6 via the A1 domain [2, 3] . von Willebrand disease (VWD) is an inherited defect of VWF structure or quantity [4] . Multiple subtypes of VWD exist that include qualitative and quantitative anomalies [4] . Type 2M VWD is a qualitative variant of VWD, characterized by a specific defect in platelet adhesion and/or collagen binding. Type 2M VWD is diagnosed by a marked decrease in VWF ristocetin cofactor activity (VWF:RCo) relative to VWF antigen (VWF: Ag) in the presence of a normal multimer distribution [5] .
The type 2M VWD category also includes collagen binding defects [4] . A decreased VWF:RCo/VWF:Ag ratio (< 0.6-0.7) is indicative of the presence of a dysfunctional VWF [6] . Type 2A VWD is also a qualitative defect in VWF. In type 2A VWD, mutations affect the multimer structure of VWF with a loss of HMWM, and concomitant loss of GPIba binding. Some type 2A variants have altered ADAMTS-13 cleavage of VWF [7] . Type 2A VWD is diagnosed by a decrease in VWF:RCo/VWF:Ag ratio, < 0.6-0.7, with a loss of HMWM [5] .
In a study by Castaman measuring gastrointestinal bleeding, 2A VWD subtypes had a higher bleeding tendency than 2M VWD subtypes [8] . Increased bleeding risk may be attributed to the lack of HMWM in type 2A VWD [8] . Accurate and efficient classification of VWD mutations can dictate therapeutic strategy for VWD patients, especially when in high-risk bleeding situations. Alternately, misdiagnosis of a normal individual as having VWD can lead to unnecessary treatment and expense. We examined five VWF sequence variants identified through the Zimmerman Program for the Molecular and Clinical Biology of VWD, all originally classified as type 2M.
Methods

Study subjects
Subjects for this research project were enrolled in the Zimmerman Program for the Molecular and Clinical Biology of VWD (Zimmerman Program) following informed consent. The study is comprised of healthy controls, subjects with any diagnosed type of VWD and immediate family members from sites across the USA. Subjects were prompted with a questionnaire to assess bleeding severity and assign a bleeding score [9] . A panel of laboratory tests, including factor VIII activity (FVIII), VWF antigen (VWF:Ag), ristocetin cofactor activity (VWF:RCo) and multimer distribution, were performed, as previously described, on plasma samples obtained at the time of enrollment from each subject [10] .
Five subjects enrolled with type 2M VWD who had novel or atypical VWF variants were selected for further study. Novel and atypical variants were defined as 2M VWD variants that have not been described in depth throughout the literature. Criteria involving the selection of a 2M subject included a VWF:RCo/VWF:Ag ratio < 0.6, as well as a normal multimer distribution on plasma samples obtained from the index case. VWF sequencing was performed on all subjects as previously described [11] . All family members had targeted VWF sequencing performed to evaluate the presence of the variant found in that family's index case.
Synthesis of variant VWF constructs
The QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA) was used to synthesize recombinant VWF constructs to include 1283Y, 1349C, 1374C, 1453N and 1162L variants in the pCINeo plasmid. DNA containing the VWF constructs was purified and expressed in HEK293T cells for each variant, as well as a wild-type (WT) VWF construct for a positive control, and an empty pCINeo vector (mock) for a negative control. Supernatants of HEK293T cells that contained VWF were collected at 72 h for analysis by ELISA as described below. Additional transfections were performed using a 1:1 ratio of variant DNA to wild-type human recombinant VWF (in the pCDNA3.1 myc his vector) to mimic the heterozygous state.
VWF assays
Expression of variants was analyzed by ELISA for VWF: Ag as described previously [10] . The wild-type, mock and variant constructs were serially diluted in ELISA block buffer and tested in triplicate at three different dilutions. Biotinylated anti-VWF monoclonal antibodies (AVW-4 and VWF-15, Blood Research Institute, Milwaukee, WI, USA) were added at 1 mcg mL À1 for detection of bound VWF. Retention of variants was measured by performing VWF:Ag on the cell lysates as previously described [12] . To measure collagen 4 binding, the ELISA plate was coated with collagen type 4 (Southern BioTech, Birmingham, AL, USA) diluted to 1 mcg mL À1 as previously described [13] .
The presence of VWF was measured by a combination of biotinylated anti-VWF monoclonal antibodies (AVW-1 and AVW-15, Blood Research Institute). To measure collagen 3 binding, the ELISA plate was coated with collagen type 3 (Southern BioTech) diluted to 1 mcg mL À1 as previously described [14] . Platelet GPIba binding (VWF: GPIbM) was tested using a 96-well Immulon-4 HBX plate (Thermo Scientific, Rochester, NY, USA) as previously described, using an anti-GPIb monoclonal antibody for capture of the recombinant GPIba and a combination of biotinylated anti-VWF monoclonal antibodies (AVW-1 and AVW-15, Blood Research Institute) for detection in the absence of ristocetin [15] . VWF multimers were analyzed using sodium dodecyl sulfate agarose gel electrophoresis for all variant constructs. Multimer protein products were then transferred to a poly(vinylidene difluoride) (PVDF) membrane. Immuno-detection of multimers was performed as previously described using a combination of anti-VWF monoclonal antibodies (105.4, AVW-1 and AVW-5, Blood Research Institute) [16] .
Results
Type 2M VWD subjects
Five subjects enrolled in the Zimmerman Program with a pre-existing diagnosis of type 2M VWD were evaluated. At the time of evaluation, 14 subjects in the study carried a diagnosis of type 2M and had DNA sequencing results available, but many of the sequence variants found had been previously characterized [17, 18] . Baseline laboratory characteristics, including VWF levels, bleeding scores and sequence variants, are detailed in Table 1 . These were similar to the values seen for other type 2M subjects enrolled in the Zimmerman Program (mean VWF:Ag 50 IU dL À1 and mean VWF:RCo 24 IU dL À1 for type 2M subjects recruited to date). Each subject had a decreased VWF:RCo/VWF:Ag ratio less than 0.6, but normal multimer distribution, consistent with a clinical diagnosis of type 2M VWD. No subject had an elevated VWF propeptide/VWF:Ag ratio. Genetic variants in four subjects were located in the A1 domain of the VWF gene, with one subject possessing a mutation in the D3 domain ( Fig. 1) . Subjects with p.P1162L and p.R1374C exhibited normal bleeding scores of 2, whereas subjects with p.Y1349C, p.I1453N and p.D1283Y exhibited elevated bleeding scores of 8, 11 and 12, respectively. The median bleeding score for the entire type 2M Zimmerman cohort was 11. Values of > 2 are abnormal for children, with the cut-off increasing to > 3 for adult men and > 5 for adult women. Interestingly, subjects had varied bleeding scores but a similar range of VWF:RCo/VWF:Ag ratios. The VWF:RCo/VWF:Ag ratio alone did not predict bleeding symptoms in this group of subjects. Bleeding score measurements showed no correlation with VWF:Ag, VWF: RCo or VWF:GPIbM.
Affected family members
Through the Zimmerman Program, family members of each subject were investigated. The index case and two family members with p.P1162L had a normal clinical phenotype with normal bleeding scores in the setting of decreased VWF:RCo/VWF:Ag ratios. The index case subject with variant p.R1374C had a normal bleeding score. Twenty-five family members were tested, some affected with VWD. With the exception of one p.R1374C family member having a high bleeding score, all other 24 family members had normal bleeding scores. There were six pediatric (under 18 years old) members of this family at the time of draw, all of whom had normal bleeding scores. Other family members were older than 18 years. The index case subject with variant p.Y1349C had a high bleeding score and had five affected family members with varied bleeding scores, ranging from 4 to 14. The index case with variant p.D1283Y also had a high bleeding score, and a single affected family member with a comparable high bleeding score of 13. The index case subject with variant p.I1453N had a high bleeding score but had no affected family members enrolled to analyze.
VWF secretion
Classic type 2M VWD is thought to have normal VWF secretion with a specific defect in VWF function, Fig. 2A) . Cell lysates were also examined to look at intracellular retention of VWF. 1283Y, 1349C and 1374C all had VWF:Ag in the cell lysate at or higher than the level seen for WT VWF, suggesting intracellular retention. 1453N had lysate levels that were approximately half those seen for the WT VWF, suggesting a defect in VWF formation as well as secretion (data not shown).
VWF collagen binding
Variant 1162L demonstrated normal binding to collagen 3 and 4 that was similar to wild type (Fig. 2B) . Conversely, variants 1283Y and 1374C showed decreased VWF:CB3/VWF:Ag, with a more than 4-fold decrease in collagen 3 and collagen 4 binding compared with WT (P < 0.05). Variant 1349C showed a non-significant decrease in collagen 4 binding. Because 1453N was not secreted, no collagen binding was observed.
GPIba binding
GPIba binding was absent in variants 1283Y, 1349C and 1374C on VWF:GPIbM ELISA assay. Variant 1162L had platelet GPIb binding similar to that seen for wildtype VWF (Fig. 2C) . As expected, given the lack of expression, no binding was observed for 1453N.
Heterozygous expression
To mimic the heterozygous state seen in patients, 1283Y, 1349C, 1374C and 1453N were co-transfected with a wildtype VWF. Secretion was reduced to half of the wild-type VWF for 1283Y, 1374C and 1453N. All heterozygous variants had normal binding to collagen 3 and 4 and platelet GPIb. Figure 3 shows the comparison of homozygous VWF multimer distribution with the heterozygous VWF multimer distribution. The WT VWF and variant VWF were labeled in different colors, which demonstrated the predominance of multimers from the WT construct with minimal contribution of variant VWF for 12873Y, 1374C and 1453N. For 1349C, both WT and variant constructs contributed to the normal multimer distribution (Figure S1 ). Table 2 shows relative laboratory comparisons of the VWF variants to their heterozygous wild-type counterpart. The normal results may therefore reflect the predominance of WT VWF in the heterozygous expression. 
Discussion
Each of the five variants studied here was originally classified as type 2M VWD based on a low plasma VWF: RCo/VWF:Ag ratio in the setting of normal VWF multimer distribution. However, in vitro studies of homozygous 1283Y, 1349C, 1374C, 1453N and 1162L demonstrate behavior inconsistent with a diagnosis of classical type 2M VWD.
Variant p.P1162L: normal variant
When first discovered, VWF variant p.P1162L was categorized as type 2M. This classification was because of the decreased VWF:RCo/VWF:Ag of 0.5, noted in Table 1 . However, in vitro, 1162L presented as phenotypically identical to the wild-type VWF. In Fig. 2(A) , 1162L is secreted in the HEK293T cells to a similar degree as wildtype VWF. Furthermore, Fig. 2 (B and C) depicts binding to collagen 3, collagen 4 and platelet GPIba at the same capacity as wild-type VWF. The p.P1162L variant presents as a wild-type phenotype both in vitro as shown above and in vivo, with a normal bleeding score of 2 in the index case and affected family members. The index case also had a VWF:RCo well above the lower limit of normal.
Variant p.P1162L is located in the D3 binding domain. Perhaps because p.P1162L is not located within the A1 domain, this does not hinder platelet binding. The most likely explanation for the low VWF:RCo/VWF:Ag ratio is the presence of a homozygous p.D1472H VWF A1 domain variant found both in this subject and the affected family members. This variant has previously been linked to low VWF:RCo/VWF:Ag ratios without causing clinical bleeding [10] . Based on this evidence, we would suggest that p.P1162L should not be considered a pathologic 2M VWD variant but rather included as a genetic variant of normal VWF. Variant p.P1162L has previously been identified in other Zimmerman Program index cases, including type 1, 1C, 2A and 2B VWD, all of whom had another causative variant explaining their phenotype. Type 2A VWD is characterized by a loss of HMWM and intermediate molecular weight multimers. This arises from either a defect in synthesis or vulnerable cleavage to ADAMTS-13 [7] . A defect in HMWM could severely affect VWF's functional role of binding platelets and collagen. Although categorized as 2M VWD, variants p.D1283Y, p.R1349C and p.R1374C are most consistent with a 2A phenotype in vitro when expressed in homozygous form. Interestingly, p.I1453N had no detectable expression in vitro, which appears more consistent with a [20] [21] [22] . There is recent evidence for a variable phenotype seen with p.1374C, with patients in the same family evidencing variable bleeding as assessed by bleeding score [23] .
2M classification schema
Though all subjects were diagnosed as type 2M VWD, VWF variants 1283Y, 1349C, 1374C, 1162L and 1453N do not necessarily behave in vitro as type 2M. A 2M VWD variant has qualitative defects in VWF with a normal multimer distribution, but variants 1283Y, 1349C, 1374C and 1453N all had abnormal multimer distribution when expressed in homozygous form (Fig. 3) . However, our study is limited by the analysis of recombinant VWF in heterozygous and homozygous forms, which may not reflect the plasma VWF in affected patients.
Previous research has suggested that using VWF:RCo to measure VWF function is not the most informative schema to assess VWF's in vivo function [24] . Given the high coefficient of variation with the VWF:RCo [25, 26] , relying on this assay to diagnose type 2 variants can be problematic. The VWF:GPIbM assay has been considered a potential replacement for the VWF:RCo [27] . In this group, the VWF:GPIbM assay did not uniformly identify a decrease in VWF function. Only the subjects with p.D1283Y and p.Y1349C had decreased VWF:GPIbM/VWF:Ag ratios. Although the ratio would be expected to be normal for the subject with p.P1162L, the normal ratios in the subjects with p.R1374C and p.I1453N may have been secondary to variable secretion [19] . It is also possible that the VWF: RCo is an aberrant result and p.I1453N is more akin to a type 3 variant.
All subjects had normal plasma collagen binding with both collagen 3 and collagen 4, in addition to a normal multimer distribution in plasma, despite the lack of normal multimer distribution for the homozygous expressed variant constructs 1283Y, 1349C, 1374C and 1453N in vitro. This may be in part because of our inability to detect subtle multimer defects. It is possible that in patient plasma, the wild-type VWF allele is dominant. This would match with the normalization of results seen with heterozygous expression, where normalization of the multimer distribution was seen for all variants. That explanation, however, fails to explain the decrease in VWF:RCo and/or VWF:GPIbM seen on plasma testing of the affected patients. This may be a result of differences in secretion of VWF, additional VWF variants or modifier protein variants, or the presence or absence of other coagulation defects that could modify the phenotype. It may be that all type 2M variants have a qualitative defect affecting VWF function, with some also affecting VWF secretion, whereas all type 2A variants have loss of high-molecular-weight multimers with a corresponding qualitative defect in VWF function (Fig. 4) Clinical laboratory variability may reflect our imperfect assays, such that some variants may be alternately classified as either type 2A or type 2M. It should also be noted that collagen binding defects without a concomitant platelet binding defect fall into the category of type 2M VWD; however, none of the variants in this analysis showed collagen binding defects.
We propose that the current classification schema of type 2A VWD vs. type 2M VWD does not completely encompass certain variants, whose laboratory phenotype may vary despite the presence of a unifying genetic mutation. In terms of laboratory diagnosis, multimer distribution may not be required in order to ensure appropriate treatment of affected patients. Clinically, classifying these as type 2A/2M is sufficient to recommend to clinicians the use of a von Willebrand factor containing concentrate for treatment, particularly if no clinical response to desmopressin is obtained. Some of these variants have previously been labeled 'unclassified', which does not alleviate clinical confusion as to the phenotype. Classic type 2A VWD has a known association of increased gastrointestinal bleeding with type 2A VWD that is not seen in type 2M VWD [8] . Classic type 2M VWD is generally less symptomatic. The group with overlap in laboratory expression may also have an overlap in phenotype, but more work is required to characterize this interesting group of variants in flow-based models [28, 29] . Addendum A. L. Doruelo performed experiments, wrote the manuscript, and assisted in research design. S. L. Haberichter performed experiments, assisted in research design, and edited the manuscript. P. A. Christopherson collected subject data, edited the manuscript, and assisted in research design. L. N. Boggio collected subject data and edited the manuscript. S. Gupta collected subject data and edited the manuscript. S. R. Lentz collected subject data and edited the manuscript. A. D. Shapiro collected subject data and edited the manuscript. R. R. Montgomery assisted in research design and edited the manuscript. V. H. Flood supervised experiments, designed the research, and wrote the manuscript.
